< Back to previous page

Project

Development of theranostic somatostatin analogues for the treatment of neuroendocrine tumors

Over the past decades somatostatin-based radiopharmaceuticals e.g. [68Ga]Ga-DOTATATE and [177Lu]Lu-DOTATATE have been used to diagnose and treat NET patients with great success. Al18F-NOTA-octreotide, a promising 18F-labeled somatostatin analogue and potential alternative for 68Ga-DOTA-peptides, has recently been shown to be a viable clinical alternative. Ideally, the same precursor (combination of chelator-linker-vector) should be used for production of both diagnostic and therapeutic radioprobes with very similar (e.g. Al18F/213Bi/177Lu) or identical (e.g. complementary Tb-radionuclides) pharmacokinetic properties, allowing accurate, personalised dosimetry estimation and radionuclide therapy of NET patients.

In this study we evaluated the versatile and highly effective chelators 3p-C-NETA and 3p-C-DEPA as potential theranostic agents capable of complexing both diagnostic and therapeutic radionuclides, including β- and α-emitters. As a proof-of-principle 3p-C-NETA-TATE was investigated as a theranostic agent for NETs and finally, SSTR agonist and antagonist were evaluated to identify the optimal vector molecule for efficient in vivo targeting of NETs. 

Date:1 Oct 2018 →  15 Dec 2022
Keywords:nuclear medicine, neuroendocrine tumours, radionuclides
Disciplines:Medical imaging and therapy, Other chemical sciences, Chemical product design and formulation, Biomaterials engineering, Medicinal products
Project type:PhD project